Last reviewed · How we verify
chemotherapy treatment called GPOH
chemotherapy treatment called GPOH is a Small molecule drug developed by Princess Maxima Center for Pediatric Oncology. It is currently in Phase 1 development.
At a glance
| Generic name | chemotherapy treatment called GPOH |
|---|---|
| Sponsor | Princess Maxima Center for Pediatric Oncology |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- chemotherapy treatment called GPOH CI brief — competitive landscape report
- chemotherapy treatment called GPOH updates RSS · CI watch RSS
- Princess Maxima Center for Pediatric Oncology portfolio CI
Frequently asked questions about chemotherapy treatment called GPOH
What is chemotherapy treatment called GPOH?
chemotherapy treatment called GPOH is a Small molecule drug developed by Princess Maxima Center for Pediatric Oncology.
Who makes chemotherapy treatment called GPOH?
chemotherapy treatment called GPOH is developed by Princess Maxima Center for Pediatric Oncology (see full Princess Maxima Center for Pediatric Oncology pipeline at /company/princess-maxima-center-for-pediatric-oncology).
What development phase is chemotherapy treatment called GPOH in?
chemotherapy treatment called GPOH is in Phase 1.